30 results on '"Branson, Janice"'
Search Results
2. Data science in pharmaceutical R&D: the DISRUPT-DS industry roundtable
3. Democratizing data at Novartis through clinical trial data access
4. Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis
5. Synthetic data use: exploring use cases to optimise data utility
6. Decentralized clinical trials: scientific considerations through the lens of the estimand framework
7. Evaluating the re-identification risk of a clinical study report anonymized under EMA Policy 0070 and Health Canada Regulations
8. A Graphical Approach for Incorporating Prior Knowledge When Determining a Sample Size for the Assessment of Batched Products
9. Good Data Science Practice: Moving toward a Code of Practice for Drug Development (Rejoinder)
10. Academic Performance of Transfer and Non-transfer Students in Introductory Agriculture Courses
11. Good Data Science Practice: Moving Towards a Code of Practice for Drug Development
12. Addressing Food Insecurity in Food Deserts for Children Through Container Gardening
13. Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis
14. Assessment of Lumiracoxib Bioavailability from Targeted Sites in the Human Intestine Using Remotely Activated Capsules and Gamma Scintigraphy
15. Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials
16. Additional file 3 of Evaluating the re-identification risk of a clinical study report anonymized under EMA Policy 0070 and Health Canada Regulations
17. Additional file 1 of Evaluating the re-identification risk of a clinical study report anonymized under EMA Policy 0070 and Health Canada Regulations
18. Additional file 2 of Evaluating the re-identification risk of a clinical study report anonymized under EMA Policy 0070 and Health Canada Regulations
19. Additional file 4 of Evaluating the re-identification risk of a clinical study report anonymized under EMA Policy 0070 and Health Canada Regulations
20. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study
21. Secondary use of data: unleashing data assets to create value.
22. EFSPI/PSI working group on data sharing: accessing and working with pharmaceutical clinical trial patient level datasets – a primer for academic researchers
23. Protecting patient privacy when sharing patient-level data from clinical trials
24. Best practice for analysis of shared clinical trial data
25. Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056
26. Lumiracoxib Does Not Affect Methotrexate Pharmacokinetics in Rheumatoid Arthritis Patients
27. Antagonism of mGluR5 in Fragile X: A Randomized, Placebo-Controlled, Proof-of-Concept Study of AFQ056, a Novel, Sub-Type Selective mGluR5 Antagonist
28. Epigenetic Modification of the FMR1Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056
29. Spatial variability of soil solution nitrates and soil morphology as effected by long term management on a Highland Rim site
30. Soil genesis and classification in the Whiteoak Mountain fault block in East Tennessee
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.